Cover Image
市場調查報告書

Erytech Pharma SA的產品平台分析

Erytech Pharma SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321348
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Erytech Pharma SA的產品平台分析 Erytech Pharma SA - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 33 Pages
簡介

Erytech Pharma SA是總公司設置於法國的生物製藥企業,正在開發創新的癌症治療藥。開發中產品ERY-ASP是用於急性白血病的治療藥,目前正處於第三代臨床試驗中。

本報告提供Erytech Pharma SA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Erytech Pharma SA 基本資料

  • Erytech Pharma SA 概要
  • 主要資訊
  • 企業資料

Erytech Pharma SA :R&D概要

  • 主要的治療範圍

Erytech Pharma SA :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Erytech Pharma SA :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段階段的產品/聯合治療模式
    • 第一階段階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • ■Erytech Pharma SA :藥物簡介
  • asparaginase
  • Cell therapy for Phenylketonuria
  • Enhoxy
  • ERY-MET
  • ERY-VAX
  • Cell Therapy 2 for Cancer

Erytech Pharma SA :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Erytech Pharma SA :最新的開發平台資訊

Erytech Pharma SA :暫停開發的計劃

Erytech Pharma SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07305CDB

Summary

Global Markets Direct's, 'Erytech Pharma SA - Product Pipeline Review - 2015', provides an overview of the Erytech Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Erytech Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Erytech Pharma SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Erytech Pharma SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Erytech Pharma SA's pipeline products

Reasons to buy

  • Evaluate Erytech Pharma SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Erytech Pharma SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Erytech Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Erytech Pharma SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Erytech Pharma SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Erytech Pharma SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Erytech Pharma SA Snapshot
    • Erytech Pharma SA Overview
    • Key Information
    • Key Facts
  • Erytech Pharma SA - Research and Development Overview
    • Key Therapeutic Areas
  • Erytech Pharma SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Erytech Pharma SA - Pipeline Products Glance
    • Erytech Pharma SA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Erytech Pharma SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Erytech Pharma SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Erytech Pharma SA - Drug Profiles
    • asparaginase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell therapy for Phenylketonuria
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enhoxy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERY-MET
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERY-VAX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ERYTOL
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Erytech Pharma SA - Pipeline Analysis
    • Erytech Pharma SA - Pipeline Products by Target
    • Erytech Pharma SA - Pipeline Products by Route of Administration
    • Erytech Pharma SA - Pipeline Products by Molecule Type
    • Erytech Pharma SA - Pipeline Products by Mechanism of Action
  • Erytech Pharma SA - Recent Pipeline Updates
  • Erytech Pharma SA - Dormant Projects
  • Erytech Pharma SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Erytech Pharma SA, Key Information
  • Erytech Pharma SA, Key Facts
  • Erytech Pharma SA - Pipeline by Indication, 2015
  • Erytech Pharma SA - Pipeline by Stage of Development, 2015
  • Erytech Pharma SA - Monotherapy Products in Pipeline, 2015
  • Erytech Pharma SA - Phase III, 2015
  • Erytech Pharma SA - Phase II, 2015
  • Erytech Pharma SA - Phase I, 2015
  • Erytech Pharma SA - Preclinical, 2015
  • Erytech Pharma SA - Pipeline by Target, 2015
  • Erytech Pharma SA - Pipeline by Route of Administration, 2015
  • Erytech Pharma SA - Pipeline by Molecule Type, 2015
  • Erytech Pharma SA - Pipeline Products by Mechanism of Action, 2015
  • Erytech Pharma SA - Recent Pipeline Updates, 2015
  • Erytech Pharma SA - Dormant Developmental Projects,2015

List of Figures

  • Erytech Pharma SA - Pipeline by Top 10 Indication, 2015
  • Erytech Pharma SA - Pipeline by Stage of Development, 2015
  • Erytech Pharma SA - Monotherapy Products in Pipeline, 2015
  • Erytech Pharma SA - Pipeline by Top 10 Target, 2015
  • Erytech Pharma SA - Pipeline by Top 10 Route of Administration, 2015
  • Erytech Pharma SA - Pipeline by Top 10 Molecule Type, 2015
  • Erytech Pharma SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top